---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-000893"
form_type: "8-K"
ticker: "IONS"
cik: "0000874015"
company_name: "IONIS PHARMACEUTICALS INC"
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:59:56.193199+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Ionis reports TRYNGOLZA 2025 preliminary U.S. net sales of $105M, ups peak olezarsen guidance to >$2B

## Summary
- TRYNGOLZA generated $105M in preliminary 2025 U.S. net product sales, outperforming expectations as first FDA-approved FCS treatment.
- Annual peak net sales guidance for olezarsen in sHTG increased to >$2B from >$1B following strong Phase 3 data.
- Submitted sNDA for olezarsen in severe hypertriglyceridemia; potential approval and launch anticipated in 2026.
- Expects 2026 launches of zilganersen for Alexander disease (NDA in Q1) and bepirovirsen for chronic hepatitis B (with GSK).
- Five Phase 3 readouts from partnered programs planned in 2026, including pelacarsen (Novartis) and eplontersen (AstraZeneca).

## SEC filing metadata
- accession: 0001140361-26-000893
- form_type: 8-K
- ticker: IONS
- cik: 0000874015
- company_name: IONIS PHARMACEUTICALS INC
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/874015/000114036126000893/0001140361-26-000893-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/874015/000114036126000893/ef20062670_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-000893
- JSON: https://secwatch.observer/filing/0001140361-26-000893.json
- Plain text: https://secwatch.observer/filing/0001140361-26-000893.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.